Acasti Pharma Class A (NASDAQ:ACST) Sellers Covered 5.82% of Their Shorts

June 20, 2017 - By Ellis Scott

 Acasti Pharma Class A (NASDAQ:ACST) Sellers Covered 5.82% of Their Shorts

The stock of Acasti Pharma Class A (NASDAQ:ACST) registered a decrease of 5.82% in short interest. ACST’s total short interest was 160,200 shares in June as published by FINRA. Its down 5.82% from 170,100 shares, reported previously. With 16,700 shares average volume, it will take short sellers 10 days to cover their ACST’s short positions. The short interest to Acasti Pharma Class A’s float is 2.75%.

The stock decreased 0.76% or $0.01 on June 19, reaching $1.3. About shares traded. Acasti Pharma Inc (NASDAQ:ACST) has declined 3.13% since June 20, 2016 and is downtrending. It has underperformed by 19.83% the S&P500.

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The company has market cap of $19.13 million. The Firm is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids derived from krill oil. It currently has negative earnings. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG).

More notable recent Acasti Pharma Inc (NASDAQ:ACST) news were published by: Marketwatch.com which released: “1.3049” on January 23, 2013, also Marketwired.com with their article: “Acasti Pharma Announces Pricing for its Public Offering of Units” published on February 10, 2017, Marketwired.com published: “Acasti Pharma Announces Proposed Offering of Units” on December 05, 2016. More interesting news about Acasti Pharma Inc (NASDAQ:ACST) were released by: Marketwatch.com and their article: “CORRECTION: Acasti Pharma Grants Stock Options” published on June 16, 2017 as well as Marketwired.com‘s news article titled: “Acasti Pharma Forms Scientific Advisory Board and Appoints Two Leading …” with publication date: March 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.